Pyxis Oncology, Inc. is a clinical-stage oncology company focused on addressing unmet medical needs in patients with solid tumors, with an immediate focus on head and neck squamous cell carcinoma (HNSCC). Its lead product candidate, micvotabart pelidotin (MICVO), is an investigational antibody-drug conjugate (ADC) targeting extradomain-B of fibronectin (EDB+FN) in the tumor microenvironment. MICVO is being studied as monotherapy and in combination with pembrolizumab (KEYTRUDA) in recurrent/metastatic HNSCC and other solid tumors.
expected 2026-11-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-23 | 2025-12-31 | 0001193125-26-118532 | EDGAR | 96K words |
| 2025-03-18 | 2024-12-31 | 0000950170-25-040771 | EDGAR | 94K words |
| 2024-03-21 | 2023-12-31 | 0000950170-24-034868 | EDGAR | 128K words |
| 2023-03-22 | 2022-12-31 | 0000950170-23-009046 | EDGAR | — |
| 2022-03-29 | 2021-12-31 | 0000950170-22-004850 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-13 | 2026-06-30 | 0001193125-26-347913 | EDGAR | 57K words |
| 2025-11-03 | 2025-09-30 | 0001193125-25-261696 | EDGAR | 55K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108906 | EDGAR | 55K words |
| 2025-05-15 | 2025-03-31 | 0000950170-25-071996 | EDGAR | 52K words |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124602 | EDGAR | 63K words |
| 2024-08-14 | 2024-06-30 | 0000950170-24-097073 | EDGAR | 62K words |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059099 | EDGAR | 61K words |
| 2023-11-07 | 2023-09-30 | 0000950170-23-060354 | EDGAR | 71K words |
| 2023-08-11 | 2023-06-30 | 0000950170-23-041605 | EDGAR | 64K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-020836 | EDGAR | 60K words |
| 2022-11-01 | 2022-09-30 | 0000950170-22-020701 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0000950170-22-017222 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-09 | 0001193125-26-385901 | EDGAR | 3K words |
| 2026-09-08 | 0001193125-26-384386 | EDGAR | 1K words |
| 2026-08-13 | 0001193125-26-347911 | EDGAR | 3K words |
| 2026-03-23 | 0001193125-26-118525 | EDGAR | 4K words |
| 2026-02-06 | 0001193125-26-041169 | EDGAR | 1K words |
| 2025-12-18 | 0001193125-25-323704 | EDGAR | 2K words |
| 2025-11-03 | 0001193125-25-261689 | EDGAR | 3K words |
| 2025-08-14 | 0000950170-25-108898 | EDGAR | 2K words |
| 2025-08-04 | 0000950170-25-101618 | EDGAR | 1K words |
| 2025-07-03 | 0000950170-25-093456 | EDGAR | 1K words |
85 total filings indexed. 58 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001782223 |
| Ticker | PYXS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.pyxisoncology.com |
| Listed | 2021-10-08 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/PYXS (~200 tokens, structured JSON with cryptographic provenance)